The Breast Cancer Program was established in 1994 and has been led by Lewis Chodosh, MD, PhD and Angela DeMichele, MD, MSCE since 2005. Members of the Breast Cancer Program are focused on understanding the underlying causes of breast cancer to improve the detection, prevention and treatment of this disease. Program members work to achieve this goal by focusing on four key thematic areas: 1) Elucidation of the molecular mechanisms of breast cancer development and progression; 2) Improvements in genetic risk assessment and development of novel prevention strategies; 3) Development of novel imaging approaches to improve breast cancer detection and the assessment of therapeutic response; and 4) Translation of laboratory discoveries to novel therapeutics and biomarkers of response/outcome. These scientific goals are accomplished through four thematic groups: Breast Cancer Biology, Cancer Risk Evaluation and Prevention, Breast Imaging, and Therapeutics and Biomarkers. Members are highly interactive, as reflected in their leadership of four collaborative grants, including two NCI UOIs, an NCI U24, and a Department of Defense Breast Cancer Center of Excellence. In addition to facilitating intra- and interprogrammatic collaborations, program leadership has emphasized breast cancer clinical research as a major focus, recruited external faculty who bring important new expertise to the Program, and participated in major ACC retreats that emphasize breast cancer research. The ACC's investment in clinical/clinical research efforts, particularly the Rena Rowan Breast Center, has facilitated patient-oriented research. The Breast Cancer Program consists of 16 faculty members from seven departments in the School of Medicine and School of Arts and Sciences. These members have $8,513,166 in cancer-related grant funding (annual direct costs), of which $7,729,386 is peer-reviewed and $2,510,558 is NCI-funded. During the last funding period, members of the Breast Cancer Program published 390 cancer-related papers, of which 11% were the result of intra-programmatic collaborations and 42% were the result of inter-programmatic collaborations.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA016520-39
Application #
8823502
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
Budget Start
2014-12-01
Budget End
2015-11-30
Support Year
39
Fiscal Year
2015
Total Cost
$113,546
Indirect Cost
$85,970
Name
University of Pennsylvania
Department
Type
DUNS #
042250712
City
Philadelphia
State
PA
Country
United States
Zip Code
19104
Morrison, Alexander H; Byrne, Katelyn T; Vonderheide, Robert H (2018) Immunotherapy and Prevention of Pancreatic Cancer. Trends Cancer 4:418-428
Yan, Lesan; Amirshaghaghi, Ahmad; Huang, Dennis et al. (2018) Protoporphyrin IX (PpIX)-Coated Superparamagnetic Iron Oxide Nanoparticle (SPION) Nanoclusters for Magnetic Resonance Imaging and Photodynamic Therapy. Adv Funct Mater 28:
Ojha, Rani; Leli, Nektaria M; Onorati, Angelique et al. (2018) ER translocation of the MAPK pathway drives therapy resistance in BRAF mutant melanoma. Cancer Discov :
Han, Joseph; Lachance, Catherine; Ricketts, M Daniel et al. (2018) The scaffolding protein JADE1 physically links the acetyltransferase subunit HBO1 with its histone H3-H4 substrate. J Biol Chem 293:4498-4509
Waxman, Adam J; Clasen, Suparna; Hwang, Wei-Ting et al. (2018) Carfilzomib-Associated Cardiovascular Adverse Events: A Systematic Review and Meta-analysis. JAMA Oncol 4:e174519
Gangadhar, Tara C; Savitch, Samantha L; Yee, Stephanie S et al. (2018) Feasibility of monitoring advanced melanoma patients using cell-free DNA from plasma. Pigment Cell Melanoma Res 31:73-81
Reshef, Ran; Ganetsky, Alex; Acosta, Edward P et al. (2018) Extended CCR5 Blockade for Graft-versus-Host Disease Prophylaxis Improves Outcomes of Reduced-Intensity Unrelated Donor Hematopoietic Cell Transplantation: A Phase II Clinical Trial. Biol Blood Marrow Transplant :
Lang, Fengchao; Sun, Zhiguo; Pei, Yonggang et al. (2018) Shugoshin 1 is dislocated by KSHV-encoded LANA inducing aneuploidy. PLoS Pathog 14:e1007253
Rosenfeld, Aaron M; Meng, Wenzhao; Luning Prak, Eline T et al. (2018) ImmuneDB, a Novel Tool for the Analysis, Storage, and Dissemination of Immune Repertoire Sequencing Data. Front Immunol 9:2107
Kushner, Carolyn J; Hwang, Wei-Ting; Wang, Shiyu et al. (2018) Long-term risk of second malignancies in women after breast conservation therapy for ductal carcinoma in situ or early-stage breast cancer. Breast Cancer Res Treat 170:45-53

Showing the most recent 10 out of 1047 publications